Key Highlights
- October 30, 2026 is the FDA target action date for the biologics license application of Inovio (NASDAQ:INO) for INO-3107, a treatment for adults with recurrent respiratory papillomatosis, a rare airway disease. The date is 14 days after publication, so the event is upcoming, not announced.
- USD 36.7 million was the cash and short-term investments of Inovio (NASDAQ:INO) at June 30, 2026, excluding about USD 18.3 million of net proceeds from a July equity offering. The company expects cash to fund operations into late first quarter 2027.
- USD 6.0 million was the second quarter net loss, or USD 0.07 per share, against USD 23.5 million a year earlier. A non-cash USD 13.9 million gain on warrant liabilities drove the improvement, so the narrower loss does not mean lower spending.
- 3 designations frame the application: orphan drug, breakthrough therapy and review under the accelerated approval program. The company says the late-cycle meeting and all scheduled pre-licensure inspections are complete, a procedural step that Inovio (NASDAQ:INO) has cleared.
What Is Under Review
INO-3107 is a DNA medicine designed to train the immune system against the human papillomavirus types that cause recurrent respiratory papillomatosis, a disease where warts regrow in the airway and often require repeated surgery. The BLA is under review through the accelerated approval program, which allows approval on an early signal if a confirmatory trial follows. Inovio has not published response rates, proposed label language or efficacy data in its latest release. The FDA target action date is Friday, October 30, 2026.
The Accelerated Approval Question
The key uncertainty is eligibility for that pathway. Inovio reported an informal FDA meeting in which the agency did not discuss its preliminary file-acceptance comment on accelerated approval eligibility. The FDA also said feedback on the design of the confirmatory trial would be forthcoming, which means that requirement was still open in the company's disclosure. A complete response letter is possible, and a delayed goal date is also possible. Neither outcome would be a surprise for a first-of-kind product, though neither is forecast here.
Cash, Dilution and Launch Costs
Cash fell from USD 58.5 million at December 31, 2025. Inovio (NASDAQ:INO) sold shares and warrants in July in an underwritten offering reported at about USD 20 million, with Piper Sandler as sole manager. The company estimates about USD 18 million of third quarter net cash burn. It excludes any further financing, so another raise is plausible, and new shares dilute existing holders. A contract sales organization, Syneos Health, is preparing a launch if approval comes.
Where Things Stand
It depends. Inovio (NASDAQ:INO) has cleared inspections and the late-cycle meeting, which supports an on-time decision on October 30, 2026, but the accelerated approval pathway and confirmatory trial design remain open questions, and no efficacy figures have been published. Cash lasts into late first quarter 2027 on the company's estimate, so even approval would likely be followed by financing needs and launch costs. The next catalyst is the FDA action on October 30, followed by third quarter financial results. A rejection or delay would pressure the stock, and an approval would not remove dilution risk. This is not a forecast.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...